Over the last 20 years, much of drug manufacturing has shifted overseas, according to Johns Hopkins experts. But the work is not going to countries where the cost of labor is less than in the United States.
It’s being shifted to high income countries such as Switzerland, Ireland and Germany that have high labor costs but a tax structure that incentivizes manufacturing.
